HIV drug development: the next 25 years

Area of Science:

• Virology and Infectious Diseases
• Pharmacology and Drug Development
• Immunology

Background:

• The human immunodeficiency virus (HIV) was discovered 25 years ago, prompting intensive drug development efforts.
• Despite substantial progress, significant challenges and uncertainties remain in the optimal management of HIV infection.
• Current HIV treatment regimens require continuous evaluation and improvement to combat viral persistence and drug resistance.

Purpose of the Study:

• To review current therapeutic strategies for managing HIV infection.
• To explore novel drug targets and mechanisms for existing targets in HIV treatment.
• To project future directions in HIV drug development, including resistance avoidance and personalized therapy.

Main Methods:

• Comprehensive literature review of published research on HIV drug development and treatment.
• Analysis of current and emerging drug classes and their mechanisms of action.
• Exploration of potential novel therapeutic targets and strategies for HIV intervention.

Main Results:

• Significant advancements in antiretroviral therapy have transformed HIV from a fatal disease to a manageable chronic condition.
• Emerging drug resistance remains a critical challenge, necessitating the development of new agents and strategies.
• Pharmacogenomics and individualized therapy hold promise for optimizing treatment efficacy and minimizing adverse effects.

Conclusions:

• Continued innovation in drug discovery and development is crucial for addressing unmet needs in HIV management.
• Future HIV treatment will likely involve a combination of optimized existing therapies, novel drug classes, and personalized approaches.
• Preventing drug resistance and leveraging pharmacogenomic insights are key to achieving long-term viral suppression and improving patient outcomes.